MM cells have been reported to respond to LXR activation through changes in the intracellular cholesterol content, associated with an enhanced expression of the NK cell-activating ligands, i.e. the major histocompatibility complex class I chain-related molecule A and B (MICA and MICB), two well characterized ligands of the NK group 2D receptor (NKG2D)/CD314 activating receptor expressed in cytotoxic lymphocytes, thus making MM cells more prone to NK-mediated recognition and killing. Here, MICB is linked to Miyoshi myopathy.